相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status
Lama Ghazi et al.
JOURNAL OF HYPERTENSION (2016)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams et al.
LANCET (2015)
Effect of Spironolactone in Resistant Arterial Hypertension A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
Jan Vaclavik et al.
MEDICINE (2014)
Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways Implications in Diabetes Mellitus-Associated Obesity and Vascular Dysfunction
Ana M. Briones et al.
HYPERTENSION (2012)
Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial
Jan Vaclavik et al.
HYPERTENSION (2011)
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
Fabio de Souza et al.
HYPERTENSION (2010)
Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–aldosterone system
Beatriz Alvarez-Alvarez et al.
JOURNAL OF HYPERTENSION (2010)
Characterization of resistant hypertension - Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion
Krishna K. Gaddam et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
A novel adipokine CTRP1 stimulates aldosterone production
Jun Ho Jeon et al.
FASEB JOURNAL (2008)
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
Carmine Savoia et al.
HYPERTENSION (2008)
Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension
David A. Calhoun et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2008)
Effect of spironolactone on blood pressure in subjects with resistant hypertension
Neil Chapman et al.
HYPERTENSION (2007)
Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism
MK Nishizaka et al.
CIRCULATION (2004)
Low-renin status in therapy-resistent hypertension: a clue to efficient treatment
IK Eide et al.
JOURNAL OF HYPERTENSION (2004)
Human adipocytes secrete mineralocorticoid-releasing factors
M Ehrhart-Bornstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region
B Strauch et al.
JOURNAL OF HUMAN HYPERTENSION (2003)
Efficacy of low-dose spironolactone in subjects with resistant hypertension
MK Nishizaka et al.
AMERICAN JOURNAL OF HYPERTENSION (2003)
Hyperaldosteronism among with resistant black and white subjects hypertension
DA Calhoun et al.
HYPERTENSION (2002)
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
MH Weinberger et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
The role of spironolactone in the treatment of patients with refractory hypertension
J Ouzan et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio
BJ Gallay et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
CAJ Farquharson et al.
CIRCULATION (2000)
分享论文
